abstract |
(57) [Summary]nThe present invention relates to the cloning of the βAPP-C100 receptor (C100-R), and to genetically engineered host cells that express C100-R. Such engineered cells can be used to evaluate and screen for analogs and drugs of β-APP involved in Alzheimer's disease. |